Pure Resources (ASX:PR1) appoints sitting AML3D CEO Sean Ebert as Board Adviser, signalling a defence materials re-rate path modelled on AML3D’s playbook.
Most people who get into trading start the same way. They watch a few YouTube videos, open a demo account, feel confident for about two weeks, and then slowly realize the market does not care about their confidence. At that point, two paths open up: keep figuring it out alone, or find someone who has…
Tax Loss Selling Season Is Coming: 7 Beaten-Down ASX Stocks Most Likely to Get Dumped Before June 30
ASX Stocks Most Exposed Before June 30
Every June, billions of dollars get sold on the ASX for tax reasons rather than business reasons. With the Australian financial year ending June 30, investors are clearly losing positions to offset gains taken elsewhere. The pressure usually peaks in the final two weeks before EOFY, pushing already-weak…
With the uproar about the CGT and Negative Gearing Changes outlined in last week's budget, you'd imagine the goalposts had been moved for good...and that's not inaccurate to say.
For years, the debate around negative gearing and the capital gains tax discount has been a no-go zone. But given the Albanese government's large majority and iron-hard…
ASX manganese stocks have been far from the best performer on account manganese spending most of the past decade sitting in the background of the battery‑materials conversation. Lithium captured the headlines, nickel dominated the midstream debate, and graphite became the unexpected bottleneck.
Yet manganese has quietly become one of the most strategically important inputs in the…
Racura Oncology Surges on Trial Update
Racura Oncology (ASX: RAC) climbed 8.66 per cent on Friday to close at A$2.76, after the independent Safety Review Committee cleared the company to double the dosage level in its CPACS Phase 1 cancer trial. The first three patients in Cohort 1 showed no dose-limiting toxicities and remain alive…
